Loading...
ALVR AlloVir
No Data
News
Comment
AlloVir price target lowered to $34 from $55 at Piper Sandler
Piper Sandler analyst Christopher Raymond lowered the firm's price target on AlloVir to $34 from $55 and keeps an Overweight rating on the shares. The analyst says that with the current environment of
AlloVir, Inc. (NASDAQ:ALVR) Insider Beek Jeroen B. Van Sells 15,262 Shares
AlloVir, Inc. (NASDAQ:ALVR – Get Rating) insider Beek Jeroen B. Van sold 15,262 shares of the stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $4.40, for a tot
AlloVir, Inc. (NASDAQ:ALVR) Sees Significant Growth in Short Interest
AlloVir, Inc. (NASDAQ:ALVR – Get Rating) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totalling 6,610,000 shares, an increase of
90 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered dire
58 Stocks Moving In Thursday's Mid-Day Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) jumped 102.6% to $0.1580 after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.AppLovin
J.P. Morgan Thinks AlloVir’s Stock is Going to Recover
J.P. Morgan analyst Anupam Rama maintained a Buy rating on AlloVir (ALVR – Research Report) on May 10 and set a price target of $32.00. The company's shares closed last Wednesday at $3.26, close to i
AlloVir (NASDAQ:ALVR) Lowered to Sell at Zacks Investment Research
AlloVir (NASDAQ:ALVR – Get Rating) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research report issued on Monday, Zacks.com reports. According to Zacks, "
SVB Securities Thinks AlloVir’s Stock is Going to Recover
In a report issued on May 5, Mani Foroohar from SVB Securities reiterated a Buy rating on AlloVir (ALVR – Research Report), with a price target of $30.00. The company's shares closed last Friday at $
RGNX, FATE and ALVR are among after hours
Gainers: REGENXBIO (RGNX) +8%.Passage Bio (PASG) +6%.Yellow Corporation (YELL) +6%.Fluence Energy (FLNC) +6%.Fate Therapeutics (FATE) +4%.Losers: Cytokinetics (CYTK) -5%.Golden Entertainment GDEN -5%
Recap: AlloVir Q1 Earnings
AlloVir (NASDAQ:ALVR) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings AlloVir beat estimated earnings by 13.7